Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description.
Maria Luisa BrandiGema AricetaSigne Sparre Beck-NielsenAnnemieke M BootKarine BriotCarmen de Lucas CollantesFrancesco EmmaSandro GianniniDieter HaffnerRichard KeenElena LevtchenkoOuti MӓkitieOla NilssonDirk SchnabelLiana Tripto-ShkolnikM Carola ZillikensJonathan LiuAlina TudorM Zulf MughalPublished in: Therapeutic advances in chronic disease (2022)
The International XLH Registry is registered with clinicaltrials.gov as NCT03193476 (https://clinicaltrials.gov/ct2/show/NCT03193476), and the PASS is registered with the European Union electronic Register of Post-Authorisation Studies as EUPAS32190 (http://www.encepp.eu/encepp/viewResource.htm?id=32191).